SCN9A Antikörper (AA 1751-1946) (Biotin)

Produktnummer ABIN2483097

Produktdetails anti-SCN9A Antikörper (Biotin)

Target: SCN9A (Sodium Channel, Voltage-Gated, Type IX, alpha Subunit (SCN9A))

Bindungsspezifität: AA 1751-1946

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SCN9A Antikörper ist konjugiert mit Biotin

Applikation: Immunohistochemistry (IHC), Western Blotting (WB), Immunofluorescence (IF), Immunoprecipitation (IP), Immunocytochemistry (ICC), Antibody Array (AA)

Spezifität: Detects ~230 kDa. No cross-reactivity against other Nav channels.

Kreuzreaktivität: Hamster, Human, Maus, Ratte

Aufreinigung: Protein G Purified

Immunogen: Fusion protein amino acids 1751-1946 (C-terminus) of human Nav1.7

Klon: N68-6 (Formerly S68-6)

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise:

• WB (1:1000)
• IHC (1:1000)
• ICC/IF (1:100)
• optimal dilutions for assays should be determined by the user.

Kommentare:

1 μg/ml of ABIN2483097 was sufficient for detection of Nav1.7 in 10 μg of HEK-293 cell lysate transiently expressing Nav1.7 by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS pH 7.4, 50 % glycerol, 0.09 % sodium azide, Storage buffer may change when conjugated

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Conjugated antibodies should be stored at 4°C

Details zu SCN9A

Target: SCN9A (Sodium Channel, Voltage-Gated, Type IX, alpha Subunit (SCN9A))

Andere Bezeichnung: Nav1.7 (SCN9A Produkte)

Hintergrund: Nav1.7 is a voltage-gated sodium channel and plays a critical role in the generation and conduction of action potentials and is thus important for electrical signaling by most excitable cells. Therapeutically, the association of pain insensitivity with the loss of function of a certain sodium channel may have implications. Since Nav1.7 is not present in cardiac muscle or neurons in the central nervous system, blockers of Nav1.7 will not have direct action on these cells and thus can have less side effects than current pain medications. By performing more studies, there is a possibility to develop a new generation of drugs that can reduce the pain intensity in animals (1-3).

Gen-ID: 6335

NCBI Accession: NP_002968

UniProt: Q15858